Jarushka Naidoo: A step forward in implementing anti-PD(L)1 across growing not otherwise specified of indications?
Jarushka Naidoo shared on X:
“Ph III IMscin001 trial of Subcutaneous (sc) vs IV Atezolizumab in advanced NSCLC at Journal of Thoracic Oncology:
– mOS 10.7 v 10.1m
– median admin time sc: 7mins
– similar toxicity
A step forward in implementing anti-PD(L)1 across growing not otherwise specified of indications?”
Proceed to the article.
Source: Jarushka Naidoo/X
Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.
She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.
She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023